ASH 2023 Insights: "Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Pts With Heavily Pretreated/Refractory CML and Ph+ ALL"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

ASH 2023 Insights: "Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Pts With Heavily Pretreated/Refractory CML and Ph+ ALL"

By Insights from 2023 ASH Annual Meeting FEATURING Elias Jabbour

115 views

December 21, 2023

0 Comments

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Efficacy and Safety of Asciminib in Ph+ CML

50:34

Scripps MD Anderson Cancer Center

The Cure of Leukemias in the Next Decade: An Optimist’s View

Feat. H. Kantarjian

07:55

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes …

Feat. E. Atallah

09:51

i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje

14:39

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

Feat. C. Lai

16:25

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The New ELN Laboratory Recommendations for the Diagnosis …

Feat. N. Cross

04:02

Michael Burke

Updated Results from the BLAST and TOWER Studies: Safety and Efficac…

19:15

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: CML - Are We Doing It Right?

Feat. J. Cortés

17:30

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Rational TKI Choice in CML

Feat. M. Deininger

07:06

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Putting the CAR-T Before the Horse - Impr…

Feat. L. Shune

40:21

Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Overview of Hematopoietic Cell Transplantation

Feat. R. Salit

28:07

Indy Hematology Review

Controversies and Recommendations for the Treatment of ALL and Lymph…

Feat. W. Stock

24:44

Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

17:47

The University of Alabama at Birmingham School of Medicine

Treating CML Patients With TKI Resistance vs. TKI Intolerance

Feat. O. Jamy

04:11

Total Health

ASCO 2022 Updates in Leukemia and MDS

Feat. D. Sallman

11:02

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Predn…

Feat. M. Luskin

17:51

Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry

42:06

UNC Lineberger Comprehensive Cancer Center

Let’s Take a BiTE Out of CRS and Neurotoxicity

Feat. B. Kikani

04:45

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "The Impact of Inotuzumab Ozogamicin Treatme…

Feat. I. Aldoss

37:03

SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: ALL

Feat. E. Jabbour

Login

Login

Join VuMedi

ASH 2023 Insights: "Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Pts With Heavily Pretreated/Refractory CML and Ph+ ALL"

Related Content